{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:22:21Z","timestamp":1768742541241,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key R&D Program of China","award":["2018YFA0800603"],"award-info":[{"award-number":["2018YFA0800603"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81630021"],"award-info":[{"award-number":["81630021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100064"],"award-info":[{"award-number":["82100064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangdong Innovative Research Team Program","award":["2016ZT06Y432"],"award-info":[{"award-number":["2016ZT06Y432"]}]},{"name":"the Startup R&D Funding of Guangdong University of Technology","award":["50010102"],"award-info":[{"award-number":["50010102"]}]},{"name":"the Key Research and Development Program of Guangdong Province","award":["2019B020227003"],"award-info":[{"award-number":["2019B020227003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of \u03b1-galactosidase A (\u03b1-Gal A) activity results in the progressive systemic accumulation of its substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), which results in renal, cardiac, and\/or cerebrovascular disease and early death. Enzyme replacement therapy (ERT) is the current standard of care for FD; however, it has important limitations, including a low half-life, limited distribution, and requirement of lifelong biweekly infusions of recombinant enzymes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Herein, we evaluated a gene therapy approach using an episomal adeno-associated viral 2\/8 (AAV2\/8) vector that encodes the human <jats:italic>GLA<\/jats:italic> cDNA driven by a liver-specific expression cassette in a mouse model of FD that lacks \u03b1-Gal A activity and progressively accumulates Gb3 and Lyso-Gb3 in plasma and tissues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A pharmacology and toxicology study showed that administration of AAV2\/8-hGLA vectors (AAV2\/8-hGLA) in FD mice without immunosuppression resulted in significantly increased plasma and tissue \u03b1-Gal A activity and substantially normalized Gb3 and Lyso-Gb3 content.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Moreover, the plasma enzymatic activity of \u03b1-Gal A continued to be stably expressed for up to 38\u00a0weeks and sometimes even longer, indicating that AAV2\/8-hGLA is effective in treating FD mice, and that \u03b1-Gal A is continuously and highly expressed in the liver, secreted into plasma, and absorbed by various tissues. These findings provide a basis for the clinical development of AAV2\/8-hGLA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02894-0","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T12:02:31Z","timestamp":1693915351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systematic gene therapy derived from an investigative study of AAV2\/8 vector gene therapy for Fabry disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Mulan","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaomei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April Yuanyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunping","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-0972","authenticated-orcid":false,"given":"Allan Zijian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81:635\u201345.","journal-title":"Drugs"},{"key":"2894_CR2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/S0021-9258(18)61618-7","volume":"262","author":"P Lemansky","year":"1987","unstructured":"Lemansky P, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem. 1987;262:2062\u20135.","journal-title":"J Biol Chem"},{"key":"2894_CR3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.119.5.1137","volume":"119","author":"YA Ioannou","year":"1992","unstructured":"Ioannou YA, Bishop DF, Desnick RJ. Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J Cell Biol. 1992;119:1137\u201350.","journal-title":"J Cell Biol"},{"issue":"Pt 3","key":"2894_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/bj3320789","volume":"332","author":"YA Ioannou","year":"1998","unstructured":"Ioannou YA, Zeidner KM, Grace ME, Desnick RJ. Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. Biochem J. 1998;332(Pt 3):789\u201397.","journal-title":"Biochem J"},{"key":"2894_CR5","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2894_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00428-008-0614-9","volume":"452","author":"M Elleder","year":"2008","unstructured":"Elleder M. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 2008;452:705.","journal-title":"Virchows Arch"},{"issue":"Suppl 2","key":"2894_CR7","first-page":"S172","volume":"2","author":"RJ Desnick","year":"2006","unstructured":"Desnick RJ, Banikazemi M. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol Ther. 2006;2(Suppl 2):S172\u201385.","journal-title":"Nephrol Ther"},{"key":"2894_CR8","first-page":"317","volume":"31","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Wasserstein MP. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp. 2001;31:317\u201339.","journal-title":"Adv Nephrol Necker Hosp"},{"key":"2894_CR9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int. 2003;64:801\u20137.","journal-title":"Kidney Int"},{"key":"2894_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","volume":"324","author":"W von Scheidt","year":"1991","unstructured":"von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, H\u00fcbner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium. N Engl J Med. 1991;324:395\u20139.","journal-title":"N Engl J Med"},{"key":"2894_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, et al. An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288\u201393.","journal-title":"N Engl J Med"},{"key":"2894_CR12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, et al. A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711\u201322.","journal-title":"Am J Hum Genet"},{"key":"2894_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"2894_CR14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet"},{"key":"2894_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","volume":"61","author":"S Kornfeld","year":"1992","unstructured":"Kornfeld S. Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors. Annu Rev Biochem. 1992;61:307\u201330.","journal-title":"Annu Rev Biochem"},{"key":"2894_CR16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338\u201346.","journal-title":"Ann Intern Med"},{"key":"2894_CR17","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19: 100454.","journal-title":"Mol Genet Metab Rep"},{"key":"2894_CR18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"2894_CR19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"2894_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int"},{"key":"2894_CR21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med"},{"key":"2894_CR22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430\u20138.","journal-title":"Genet Med"},{"key":"2894_CR23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9: e1003632.","journal-title":"PLoS Genet"},{"key":"2894_CR24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","volume":"32","author":"X Wu","year":"2011","unstructured":"Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP, Schiffmann R, Boudes P, Lockhart DJ, Valenzano KJ, et al. A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat. 2011;32:965\u201377.","journal-title":"Hum Mutat"},{"key":"2894_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.10.016","volume":"20","author":"MG Biferi","year":"2021","unstructured":"Biferi MG, Cohen-Tannoudji M, Garc\u00eda-Silva A, Souto-Rodr\u00edguez O, Vi\u00e9itez-Gonz\u00e1lez I, San-Mill\u00e1n-Tejado B, Fern\u00e1ndez-Carrera A, P\u00e9rez-M\u00e1rquez T, Teijeira-Bautista S, Barrera S, et al. Systemic treatment of Fabry disease using a novel AAV9 vector expressing \u03b1-galactosidase A. Mol Ther Methods Clin Dev. 2021;20:1\u201317.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2894_CR26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.blre.2015.03.002","volume":"29","author":"E Lheriteau","year":"2015","unstructured":"Lheriteau E, Davidoff AM, Nathwani AC. Haemophilia gene therapy: progress and challenges. Blood Rev. 2015;29:321\u20138.","journal-title":"Blood Rev"},{"key":"2894_CR27","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","volume":"9","author":"F Puzzo","year":"2017","unstructured":"Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med. 2017;9:eaam6375.","journal-title":"Sci. Transl. Med"},{"key":"2894_CR28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/hmg\/ddac209","volume":"32","author":"CJ Rouse","year":"2023","unstructured":"Rouse CJ, Hawkins K, Kabbej N, Dalugdug J, Kunta A, Kim MJ, Someya S, Herbst Z, Gelb M, Dinelli I, et al. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector. Hum Mol Genet. 2023;32:417\u201330.","journal-title":"Hum Mol Genet"},{"key":"2894_CR29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/mt.2008.15","volume":"16","author":"DD Koeberl","year":"2008","unstructured":"Koeberl DD, Pinto C, Sun B, Li S, Kozink DM, Benjamin DK Jr, Demaster AK, Kruse MA, Vaughn V, Hillman S, et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther. 2008;16:665\u201372.","journal-title":"Mol Ther"},{"key":"2894_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","volume":"9","author":"RJ Ziegler","year":"2004","unstructured":"Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 2004;9:231\u201340.","journal-title":"Mol Ther"},{"key":"2894_CR31","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1073\/pnas.051634498","volume":"98","author":"SC Jung","year":"2001","unstructured":"Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A. 2001;98:2676\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2894_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2008.10.017","volume":"96","author":"K Ogawa","year":"2009","unstructured":"Ogawa K, Hirai Y, Ishizaki M, Takahashi H, Hanawa H, Fukunaga Y, Shimada T. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period. Mol Genet Metab. 2009;96:91\u20136.","journal-title":"Mol Genet Metab"},{"key":"2894_CR33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","volume":"15","author":"RJ Ziegler","year":"2007","unstructured":"Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH. Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther. 2007;15:492\u2013500.","journal-title":"Mol Ther"},{"key":"2894_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/8904_2015_475","volume":"30","author":"T Higuchi","year":"2016","unstructured":"Higuchi T, Kobayashi M, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, Eto Y, Maeda S, Ohtake A, Ida H, et al. Identification of cryptic novel \u03b1-galactosidase a gene mutations: abnormal mRNA splicing and large deletions. JIMD Rep. 2016;30:63\u201372.","journal-title":"JIMD Rep"},{"key":"2894_CR35","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, et al. Alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A. 1997;94:2540\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2894_CR36","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994\u20132004.","journal-title":"N Engl J Med"},{"key":"2894_CR37","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357\u201365.","journal-title":"N Engl J Med"},{"key":"2894_CR38","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017;377:2519\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"2894_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, Kia A, Tam LCS, McIntosh J, Spiewak J, Mills K, Heywood W, Chisari E, Castaldo N, Verhoef D, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30(6):487\u2013502.","journal-title":"Gene Ther"},{"key":"2894_CR40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","volume":"18","author":"M Yasuda","year":"2020","unstructured":"Yasuda M, Huston MW, Pagant S, Gan L, St Martin S, Sproul S, Richards D, Ballaron S, Hettini K, Ledeboer A, et al. AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction. Mol Ther Methods Clin Dev. 2020;18:607\u201319.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2894_CR41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","volume":"146","author":"JT Clarke","year":"2007","unstructured":"Clarke JT. Narrative review: Fabry disease. Ann Intern Med. 2007;146:425\u201333.","journal-title":"Ann Intern Med"},{"key":"2894_CR42","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","volume":"19","author":"JB Nietupski","year":"2011","unstructured":"Nietupski JB, Hurlbut GD, Ziegler RJ, Chu Q, Hodges BL, Ashe KM, Bree M, Cheng SH, Gregory RJ, Marshall J, et al. Systemic administration of AAV8-\u03b1-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther. 2011;19:1999\u20132011.","journal-title":"Mol Ther"},{"key":"2894_CR43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","volume":"68","author":"YA Ioannou","year":"2001","unstructured":"Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68:14\u201325.","journal-title":"Am J Hum Genet"},{"key":"2894_CR44","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE. 2010;5: e15033.","journal-title":"PLoS ONE"},{"key":"2894_CR45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/10430340252939041","volume":"13","author":"RJ Ziegler","year":"2002","unstructured":"Ziegler RJ, Li C, Cherry M, Zhu Y, Hempel D, van Rooijen N, Ioannou YA, Desnick RJ, Goldberg MA, Yew NS, et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther. 2002;13:935\u201345.","journal-title":"Hum Gene Ther"},{"key":"2894_CR46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","volume":"1690","author":"S Ishii","year":"2004","unstructured":"Ishii S, Yoshioka H, Mannen K, Kulkarni AB, Fan JQ. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta. 2004;1690:250\u20137.","journal-title":"Biochim Biophys Acta"},{"issue":"21","key":"2894_CR47","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.3390\/ijms21218080","volume":"21","author":"I Simonetta","year":"2020","unstructured":"Simonetta I, Tuttolomondo A, Daidone M, Pinto A. Biomarkers in Anderson-Fabry disease. Int J Mol Sci. 2020;21(21):8080.","journal-title":"Int J Mol Sci"},{"key":"2894_CR48","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1194\/jlr.M017178","volume":"52","author":"B Durant","year":"2011","unstructured":"Durant B, Forni S, Sweetman L, Brignol N, Meng XL, Benjamin ER, Schiffmann R, Shen JS. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J Lipid Res. 2011;52:1742\u20136.","journal-title":"J Lipid Res"},{"key":"2894_CR49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28:723\u201346.","journal-title":"Mol Ther"},{"key":"2894_CR50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111:1347\u201356.","journal-title":"J Clin Invest"},{"key":"2894_CR51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","volume":"110","author":"O Cao","year":"2007","unstructured":"Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 2007;110:1132\u201340.","journal-title":"Blood"},{"key":"2894_CR52","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, Zhou S, Wright JF, Jiang H, Pierce GF, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007;110:2334\u201341.","journal-title":"Blood"},{"key":"2894_CR53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.omtm.2022.04.010","volume":"25","author":"X Jin","year":"2022","unstructured":"Jin X, Su J, Zhao Q, Li R, Xiao J, Zhong X, Song L, Liu Y, She K, Deng H, et al. Liver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler. Mol Ther Methods Clin Dev. 2022;25:370\u201381.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2894_CR54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87\u2013104.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2894_CR55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2310\/6650.2002.33432","volume":"50","author":"GA Ashley","year":"2002","unstructured":"Ashley GA, Desnick RJ, Gordon RE, Gordon JW. High overexpression of the human alpha-galactosidase A gene driven by its promoter in transgenic mice: implications for the treatment of Fabry disease. J Investig Med. 2002;50:185\u201392.","journal-title":"J Investig Med"},{"key":"2894_CR56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126:162\u20138.","journal-title":"Mol Genet Metab"},{"key":"2894_CR57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","volume":"7","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Koeberl DD. Liver depot gene therapy for Pompe disease. Ann Transl Med. 2019;7:288.","journal-title":"Ann Transl Med"},{"key":"2894_CR58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.gt.3302142","volume":"11","author":"TC Harding","year":"2004","unstructured":"Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, et al. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Ther. 2004;11:204\u201313.","journal-title":"Gene Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02894-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:28:04Z","timestamp":1700299684000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02894-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02894-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}